Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology. Radius' lead product, TYMLOSÂŽ (abaloparatide) injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide patch for potential use in osteoporosis; the investigational drug elacestrant (RAD1901) for potential use in hormone-receptor positive breast cancer; and the investigational drug RAD140 under investigation for potential use in hormone-receptor positive breast cancer. Source
No articles found.
Oracle Health is developing a Digital Health Insertable (Under The Skin) Cardiac D...
Oracle Health is developing a Digital Health In...
Neuralstem is a biopharmaceutical company developing novel treatments for nervous ...
Neuralstem is a biopharmaceutical company devel...
Neon Therapeutics is a clinical-stage immuno-oncology company leading in the field...
Neon Therapeutics is a clinical-stage immuno-on...
Nektar Therapeutics is a research-based development stage biopharmaceutical compan...
Nektar Therapeutics is a research-based develop...
Benitec is a biotechnology company developing a proprietary therapeutic technology...
Benitec is a biotechnology company developing a...
Seattle-based Atossa Genetics (NASDAQ: ATOS) is a clinical-stage biopharmaceutical...
Seattle-based Atossa Genetics (NASDAQ: ATOS) is...
Pieris Pharmaceuticals, Inc. is a, clinical-stage biotechnology company committing...
Pieris Pharmaceuticals, Inc. is a, clinical-sta...
Join the National Investor Network and get the latest information with your interests in mind.